Recent Posts on This Topic | See All >
[Source: The Arizona Republic] - A Mesa-based company that markets a drug-analysis technology has completed its first examination of an investigational cancer drug being developed by a Canadian biotechnology company.
Predictive Biomarker Sciences, a for-profit company partly owned by Phoenix-based Translational Genomics Research Institute, analyzed a drug candidate being developed by Ottawa, Ontario-based PharmaGap. The analysis suggested that PharmaGap's potential drug, called GAP-107B8, attacks the membrane of colon cancer cells while having less impact on non-cancerous cells.
For more information: Mesa-based Predictive Biomarker Sciences tests cancer drug
“Arizona’s Bioscience Roadmap 2014-2025: Advancing the Biosciences and Improving Health Outcomes,” is available along with its supplement, “Summary of Goals, Strategies, and Potential Actions.” The updated Roadmap provides a long-term strategy for Arizona to achieve bioscience success over the next decade. Also, discover The State of Bioscience.